Palivizumab [188039-54-5]

TargetMol Chemicals

Palivizumab

10

Antibody

Research Use Only

Palivizumab

SDS-PAGE:93.4%;SEC-HPLC:97.6%

Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).

3 years

-20°C

12352203